SAB Biotherapeutics Inc 2022 Annual R&D Portfolio Update Call (Virtual) Transcript
Good day. We want to welcome you to our webinar today for SAB Biotherapeutics. My name is Eddie Sullivan and I am the President and CEO of SAB. As you all know, SAB is a robust, growing clinical stage biopharmaceutical company with a broad pipeline expanding multiple therapeutic indications and it's certainly our pleasure to be with you to give you more information about the continuing strategy of SAB.
To get started today, I want to call your attention to our forward-looking statements slide. And with that, we'll continue on to the next slide. First of all, by way of introduction of our experienced management team, I certainly want to call your attention to what is our new management team and this might be the first time that some of you have seen this group together.
But first of all, I want to introduce Samuel Reich who is with us today but won't be speaking. He is our Executive Chairman and Sam has experience across many biotech companies in taking companies throughs startup all the way through M&A. And so, it's our
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
